The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical study on edaravone combined with citicoline in treatment of acute cerebral infarction
Author(s): 
Pages: 408-412
Year: Issue:  4
Journal: World Phytomedicines

Keyword:  edaravoneciticolineacute ischemic cerebral infarction;
Abstract: Objective To study the clinical efficacy and safety of edaravone combined with citicoline in the treatment of acute ischemic cerebral infarction. Methods The patients(90 cases) diagnosed as acute cerebral infarction in Shanghai Tong Ren Hospital from May 2009 to May 2012 were randomly divided into edaravone group, citicoline group, and combination group, each had 30 cases. On the basis of conventional therapy, the patients in the edaravone group were given edaravone, in the citicoline group were given citicoline, while in the combination group were given edaravone combined with citicoline for 14 d. Before the treatment, 14 d, and 90 d after the administration, the clinical efficacy and the changes of superoxide dismutase(SOD), neuronspecific enolase(NSE), and high-sensitivity C-reactive protein(Hs-CRP) levels were observed, and NHISS, ADL, and MAS were tested. Results Before the treatment, SOD, NSE, and Hs-CRP levels as well as NHISS, ADL, and MAS tests scores in the three groups had no statistical difference(P > 0.05). The SOD level in the combination group was higher than that in the edaravone group(P > 0.05) and the citicoline group(P < 0.05), while NSE and Hs-CRP levels in the combination group was less than those in the edaravone group and citicoline group(P > 0.05) in 14 d after the treatment. The SOD level in the combination group was higher than that in the edaravone group and citicoline group(P < 0.05), while NSE and Hs-CRP levels in the combination group were less than those in the edaravone group and citicoline group(P < 0.05) in 90 d after the treatment. Compared with the scores before the treatment, NIHSS scores in the all three groups decreased(P < 0.05), while ADL and MAS scores increased(P < 0.05) in 14 and 90 d after the treatment. Also NIHSS scores in the combination group were significantly lower than those in the edaravone group and citicoline group(P < 0.05), and its ADL and MAS scores were significantly higher than those in the edaravone group and citicoline group(P < 0.05). On day 14, the distribution of efficacy in the combination group had statistically significant difference compared with that in the edaravone group and citicoline group(P <0.05). The effective cases and rate in the combination group were higher than the number in the edaravone group and citicoline group in 14 and 90 d after the treatment. No serious adverse reactions had been reported. Conclusion Compared the treatment with the application of edaravone or citicoline alone, the combined use of the two drugs is more effective to the removal of free radicals, neurons protecion, the recovery of nerve function, daily function, and motor function, thereby improving the condition and prognosis.
Related Articles
No related articles found